@article{3029873,
    title = "Invasive Mucormycosis in Children With Malignancies: Report From the
Infection Working Group of the Hellenic Society of Pediatric
Hematology-Oncology",
    author = "Antoniadi, Kondilia and Iosifidis, Elias and Vasileiou, Eleni and and Tsipou, Charoula and Lialias, Ioannis and Papakonstantinou, Eugenia and and Kattamis, Antonios and Polychronopoulou, Sophia and Roilides, Emmanuel and and Tragiannidis, Athanasios",
    journal = "Journal of Pediatric Hematology / Oncology",
    year = "2021",
    volume = "43",
    number = "5",
    pages = "176-179",
    publisher = "Lippincott, Williams & Wilkins",
    issn = "1077-4114, 1536-3678",
    doi = "10.1097/MPH.0000000000001931",
    keywords = "children; cancer; mucormycosis; zygomycosis; pediatric",
    abstract = "Mucormycosis is an invasive, life-threatening fungal infection that
mainly affects immunocompromised hosts. We collected data of pediatric
mucormycosis cases from all 7 Greek Hematology-Oncology Departments for
the years 2008-2017. Six cases of invasive mucormycosis diagnosed during
treatment for malignancies were included in the study. In 4 children
(66%) mucormycosis occurred within the first 20 days after diagnosis of
the underlying disease. Two cases were classified as proven mucormycosis
and 4 as probable. The most frequently recorded species was Rhizopus
arrhizus (2 patients), followed by Mucor spp (1), and Lichtheimia spp
(1). All patients received liposomal amphotericin B. Combined antifungal
treatment was used in 5 cases. Surgical excision was performed in 4
cases (66%). Two patients died at 6 and 12 months after the diagnosis,
respectively, 1 (17%) because of mucormycosis. Our data suggest that
mucormycosis may occur early after the initiation of intensive
chemotherapy in children with malignancies."
}